The Medical Letter on Drugs and Therapeutics
Two New Drugs for Homozygous Familial Hypercholesterolemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved mipomersen (Kynamro – Genzyme) and lomitapide (Juxtapid – Aegerion), each in addition to a low-fat diet and other lipid-lowering medications, to reduce cholesterol levels in patients with homozygous familial hypercholesterolemia (HoFH).

THE DISORDER — Familial hypercholesterolemia is an inherited condition most commonly caused by defects in the low-density lipoprotein (LDL) receptor gene that result in very high levels of LDL cholesterol.1 Homozygous familial hypercholesterolemia (HoFH) is the most severe form of the disease; without treatment, cardiovascular disease and death can occur in childhood. The prevalence of HoFH has been estimated to be about one per million persons; it affects about 300 patients in the US.

STANDARD TREATMENT — The standard treatment for patients with HoFH includes a low-fat diet, high doses of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Homozygous Familial Hypercholesterolemia
Article code: 1413a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian